Drug intelligence / Profile preview

amlodipine besylate + arginine

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Amlodipine besylate + arginine is a combination product consisting of **amlodipine besylate**, a long-acting dihydropyridine calcium channel blocker used as an antihypertensive and antianginal agent, together with **arginine**, an amino acid commonly marketed as L-arginine that serves as a nitric oxide precursor and may promote vasodilation. The exact identified product corresponding to this name appears to be a kit presentation rather than a single novel molecular entity, and there is limited evidence that this exact combination is a broadly established branded pharmaceutical with a distinct development program. Mechanistically, amlodipine inhibits L-type calcium influx in vascular smooth muscle to reduce peripheral vascular resistance, while arginine may increase nitric oxide production and thereby augment vasodilatory effects. The combination would most plausibly be relevant to blood pressure management or cardiovascular support, but the exact regulatory and commercial status of the specific named combination is not well characterized.

Other names
amlodipine besylate + L-arginine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on amlodipine besylate + arginine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine besylate + arginine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call